| Dr Barry Jay Asman, MD | |
|
2550 Mosside Blvd, Suite 202, Monroeville, PA 15146-3540 | |
| (412) 372-9234 | |
| (412) 372-8671 |
| Full Name | Dr Barry Jay Asman |
|---|---|
| Gender | Male |
| Speciality | Allergy & Immunology - Allergy |
| Location | 2550 Mosside Blvd, Monroeville, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407801897 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KA0200X | Allergy & Immunology - Allergy | MD035546E (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Barry Jay Asman, MD 2550 Mosside Blvd, Suite 202, Monroeville, PA 15146-3540 Ph: (412) 372-9234 | Dr Barry Jay Asman, MD 2550 Mosside Blvd, Suite 202, Monroeville, PA 15146-3540 Ph: (412) 372-9234 |
News Archive
The study projected that health costs for a typical family of four, covered through an employer-sponsored preferred provider organization, or PPO, would go up 5.4 percent - the lowest increase in the Milliman Index's 14-year history.
John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will host its Ninth Annual Neuro-Oncology Symposium on Friday, May 17th from 8:00am-1:00pm. Experts from MD Anderson, Memorial Sloan Kettering Cancer Center, Penn State Milton S. Hershey Medical Center, and the Cleveland Clinic will present advances in multidisciplinary care for cancers of the central nervous system.
Results from a new study suggest that oral contraceptives and hormone replacement therapy may yield additional benefit of protecting against the formation and rupture of brain aneurysms in women. The findings from this first-of-its-kind study by a neurointerventional expert from Rush University Medical Center were presented at the Society of Neurointerventional Surgery 7th annual meeting.
The RECOVERY Collaborative Group has released a preliminary report describing the effects of dexamethasone treatment among patients hospitalized with coronavirus disease 2019 (COVID-19).
Insmed Incorporated, a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.
› Verified 3 days ago
Dr. Jerry Lynn, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 4099 William Penn Hwy, Ste 805, Monroeville, PA 15146 Phone: 412-372-7131 Fax: 412-372-0149 |